Le Lézard
Classified in: Health
Subjects: PDT, BFA

Pulpdent celebrates 75th anniversary as a leader in dental product research, sales, and manufacturing


Looking to the future, Pulpdent continues to grow and introduce new products?ones that empower dentists, dental hygienists, and dental assistants to reach higher standards of dental care

WATERTOWN, Mass., Nov. 3, 2022 /PRNewswire/ -- Pulpdent Corporation is pleased to announce that 2022 marks 75 years as a leading company in the global dental industry. Building on a legacy of advances in dental research, Pulpdent is poised to maintain its position as a top manufacturer and seller of dental restorative materials, prevention products, and supplies. The company also plans to introduce a series of new products in the coming years that will help raise standards in dental care.  

As part of the 75th anniversary, Pulpdent has issued a new commemorative catalog that features engaging stories and previously unreleased images of Pulpdent's rich history.

"We are grateful to all who have supported us in reaching this important milestone," says Pulpdent President Fred Berk. "We have undertaken many long-term ventures in dental materials research. It has been gratifying to watch our R&D team strike new ground, particularly in bio-interactive materials that work with nature to benefit teeth and overall oral health. Today, these hard-won advances benefit clinicians and their patients worldwide."

A History of Innovation and Responsible Growth

Founded in 1947 by Dr. Harold Berk, an innovator in calcium hydroxide materials for vital pulp therapy and root canal therapy, Pulpdent remains a family-owned company well known for its innovations in dental material science. Today, Pulpdent employs more than 125 people and manufactures its diverse product portfolio in Watertown, Massachusetts, USA.

"We have concentrated on steady, sustainable growth that will ensure the long-term vitality of the business," says Pulpdent Vice President Don Berk. "But even more importantly, we have held ourselves accountable to the core principles that were championed my father, Dr. Harold Berk, who never compromised patient care. He believed deeply in dentist education and authentic, long-term patient relationships. His spirit continues to fuel our passion to develop, manufacture, and sell products that save teeth and help patients live in comfort and smile with confidence."

Shifting the Dental Paradigm for a Better Standard of Care

Traditionally, dental products were designed to have a neutral existence, play a passive role, and do no harm. The idea was that this would make them more stable and durable. Pulpdent has worked to change the paradigm, developing smart dental materials that work in concert with natural biological processes to proactively support the health of teeth and the oral environment.

Pulpdent scientists pioneered moisture friendly dental resins and created a rubberized resin molecule for use in dental materials. These efforts fueled new product development and opened the door to modern-day bio-interactive dental materials, which Pulpdent helped introduce to dentistry in 2013. The company's first bio-interactive dental material, which received FDA approval to be termed "bioactive," was ACTIVA BioACTIVE-RESTORATIVE. ACTIVA will celebrate its 10th year in the marketplace in 2023.

"ACTIVA BioACTIVE materials have been well-received and have experienced growth every year," says Pulpdent Director of Sales Marcy Buckler. "Through a wide range of educational and sales programs, much of the dental community now understands ACTIVA's unique bioactive chemistry and how it actively helps patients' teeth and overall well-being."

Crysta MCP Technology Heralds New Product Advances

Pulpdent's latest proprietary innovation, Crysta MCP technology, was introduced in January 2022 after receiving a patent from the US Patent and Trademark Office in July 2021. Features of this groundbreaking technology include the following:

"Our innovation stems from Pulpdent's genuine heart to care for people, beginning with the Pulpdent team," says Christie Bailey, Pulpdent Director of Professional Relations & International Business. "Optimal patient care is what inspired Dr. Harold Berk to establish Pulpdent 75 years ago, and it remains the driving force for our innovation to the future."

New Logo Symbolizes New Era of Commitment

As part of Pulpdent's 75th anniversary, the company has adopted a new logo and issued a special catalog that explores the company's evolution over the years. Pulpdent's new logo is part of an ongoing rebranding effort that began in 2022. It will be gradually implemented into packaging, marketing, and other corporate media going forward. The new logo is featured in the new Pulpdent 75th anniversary commemorative catalog, which is immediately available at https://www.pulpdent.com/product-catalog/.

"The Pulpdent logo transition symbolizes important changes within the company," says Pulpdent Director of Marketing Zachary Kulsrud. "It signals to the marketplace that Pulpdent has matured and accelerated its advances in dental material technology, which allow it to further advance its mission of saving teeth and helping patients smile with confidence. It also signals that its expanding leadership team is ready to take Pulpdent confidently into its next 75 years."

A Promising Future

"Looking ahead, we plan to build on our patented advancements in moisture-friendly resin, rubberized resin, and bioactive chemical technologies for dental composites," says Manager of Strategic Operations Lewis Berk. "It is an exciting time for the company and the dental professionals we serve. Moreover, it is an honor to continue to build upon the legacy of my grandfather and his vision of better dentistry for all."

About Pulpdent Corporation?Pulpdent® Corporation is a family-owned dental research and manufacturing company established in 1947 by Dr. Harold Berk. Its longstanding mission is to save teeth and help dental patients live in comfort and smile with confidence. Pulpdent products are researched and manufactured in its production facility in Watertown, Massachusetts, USA. Its first product, Pulpdent Paste, is still used today in vital pulp therapy and root canal therapy. Pulpdent has a proven legacy of investment in original dental research and new technologies, which have led to flagship products that include ACTIVAtm BioACTIVE-RESTORATIVEtm, ACTIVAtm Prestotm / Prontotm, Embracetm WetBondtm Pit & Fissure Sealant, Lime-Litetm Enhanced, and Tuff-Temptm Plus. More information and product inquiries may be directed to the company at [email protected].

MEDIA CONTACT INFORMATION:
Pulpdent Corporation
Zachary Kulsrud | Director of Marketing
(800) 343-4342 | 80 Oakland St, Watertown, MA 02472
[email protected]

Multimedia assets for this release may be downloaded at:
Media Kit - PULPDENT

Pulpdent 75th anniversary catalog cover

Pulpdent 75th anniversary logo

SOURCE Pulpdent Corporation


These press releases may also interest you

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...



News published on and distributed by: